Swiss investment company HBM Healthcare Investments AG is considering options for further operations of the portfolio company Swixx Biopharma SA, including a potential sale for 1.5 billion Swiss francs ($1.7 billion). This is reported by foreign media.
HBM Healthcare has engaged Jefferies Financial Group Inc. and Centerview Partners to evaluate the proposed transaction in terms of interest from potential investors.
Although the option of selling Swixx is preferable, HBM may decide to place Swixx assets on the stock exchange or retain them for a longer period. Mérieux Equity Partners acquired a minority stake in Swixx in 2021.
Swixx cooperates with partners in Central and Eastern Europe, and in recent years has expanded its operations in the Middle East and Latin America.
HBM Healthcare Investments AG is a Swiss healthcare investment company. The company invests in American, European, Chinese, and Indian companies in the biotechnology, medical technology, diagnostics, and digital technology sectors. The company's net asset value exceeds 1.7 billion Swiss francs ($1.9 billion). The headquarters is located in Zug (Switzerland).
Swixx Biopharma is a Swiss pharmaceutical company representing the interests of multinational biopharmaceutical corporations in countries where they do not conduct business themselves. The company's activities are concentrated in the countries of Central and Eastern Europe. The headquarters is located in Bar (Switzerland) with offices in 44 countries. Sales amount to 900 million euros ($944 million).
Read also in our Telegram channel "Mergers and acquisitions. AK&M».
